Haryana Capfin is a non-banking financial company that primarily functions as an investment vehicle for the promoter group, earning income through dividends and interest from its holdings in group entities like Maharashtra Seamless.
The company lacks a structural moat as its income is entirely dependent on the performance and dividend policies of other group companies rather than a unique product or service. Low returns on equity and capital employed confirm the absence of competitive advantages or pricing power.
Management prioritizes the accumulation of group company shares and liquid mutual funds over shareholder payouts. While the company is virtually debt-free, the reinvestment of earnings into low-yielding assets has resulted in chronically poor returns for minority shareholders.
The investment collapsed as the company functioned as a stagnant vault for the promoter's other interests rather than a productive enterprise. By failing to meet the RBI's minimum Capital Adequacy Ratio, the firm faced regulatory sanctions that crippled its ability to operate as a financial entity. The capital previously locked in Maharashtra Seamless shares suffered a permanent impairment during a sector downturn, and because management refused to diversify or pay dividends, minority shareholders were left holding a devalued shell with no path to liquidity or recovery.
RichFakir rates Haryana Capfin Ltd's business quality as poor — 39/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Haryana Capfin Ltd is trading about 11% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Haryana Capfin Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Haryana Capfin Ltd's fair value is about ₹148 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →